 Shares of Durect NASDAQ: DRRX were up 23 at 1:53 p.m. EDT on Tuesday. The gains followed the release of first-quarter results after the closing bell Monday and disappointing trial results for Genfit NASDAQ: GNFT, a fellow biotech developing a potential competitor to Durects nonalcoholic steatohepatitis NASH drug. It certainly wasnt Durects financial report from the first quarter that has investors excited. 